1991-1995 Graduated in Chemistry, University of São Paulo, Brazil
|Research Overview||The spread of metastasis to distant sites is the leading cause of death from cancer and the epithelial-mesenchymal transition (EMT) phenomenon, which occurs during normal embryonic development and tissue injuries, is also activated during the progression and metastasis from numerous cancers. The EMT process implicates complex changes in cancer cells and their local microenvironment. Factors that promote EMT in cancer are starting to be elucidated. To extend and identify in more detail the molecular events at protein and post-translational levels occurring during EMT, we are studying adenocarcinomas, such as lung, breast, pancreas, ovarian and prostate, induced to EMT using comprehensive proteomics tools. The identified proteomic molecular signatures are being used as a basis for development of multiple reaction monitoring (MRM) methods for multiplex quantification of proteins relevant to EMT by LC-MS/MS. This strategy, initially of comprehensive and detailed studying the changes of the proteome during EMT, followed by a targeted analysis aiming extensive validation of protein candidates in patient samples, will certainly uncover truly novel protein targets for extensive clinical validation focused on theranostic applications in metastatic cancer.|
Eduardo Brant de Oliveira, PhD
Sharon Pitteri, PhD
LC-MS/MS Platform (Xevo TQ-S and Acquity I-class, Waters)
1. HANASH, S.; PITTERI, S. J.; FAÇA, V. M. Mining the plasma proteome for cancer biomarkers. Nature (London), v. 425, p. 571-579, 2008.